In Vitro Diagnostics Market By Product and Services, By Technique, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

The in vitro diagnostics market was valued at $92.5 billion in 2022 and is estimated to reach $138.4 billion by 2032, exhibiting a CAGR of 4.1% from 2023 to 2032. In vitro diagnostics (IVDs) are tests that detect diseases, conditions, and infections. In vitro means these tests are typically conducted in test tubes and similar equipment, as opposed to in vivo tests, which are conducted in the body itself. In vitro diagnostics (IVD) includes a wide range of tools and techniques, including reagents, instruments, software, and services utilized for the examination of specimens such as blood, urine, stool, tissues, and various human body fluids. These diagnostic tools are essential for detecting diseases, conditions, and infections. IVD tests are conducted in various settings, including standalone laboratories, hospital-based facilities, and point of care centers.

In addition, in vitro diagnostic techniques encompass a broad array of methodologies, including clinical chemistry, tissue diagnostics, immunodiagnostics, hematology, and more. For instance, a thyroid function test involves the collection of blood from a patient, which is then analyzed to determine the level of thyroid-stimulating hormone (TSH) in the bloodstream. This test serves as a critical tool in assessing thyroid function. Furthermore, techniques such as polymerase chain reaction (PCR) are employed to identify the presence of infectious diseases such as HIV, hepatitis, and various others. The in vitro diagnostics market growth is significantly driven by increase in the prevalence of chronic diseases such as cardiovascular disorders, cancer, and infectious diseases, surge in awareness about importance of early disease diagnosis, and increase in new test launches, thus fueling the demand for IVD tests for early detection, monitoring, and management. For instance, according to American Cancer Society (ACS), about 1.9 million new cancer cases are expected to be diagnosed in the U.S. in 2023. Thus, rise in prevalence of chronic diseases drives the demand for in vitro diagnostic tests.

In addition, surge in awareness about early disease diagnosis among the general population has increased the demand for in vitro diagnostics. Awareness campaigns, educational seminars, and training programs emphasize the importance of early disease diagnosis. For instance, F. Hoffmann-La Roche Ltd., supports local community partners to run screening programs and counselling programs for diseases such as cancers, hepatitis, tuberculosis, HIV, HPV, and cardiovascular disease. Moreover, ongoing innovations in IVD products, service designs, and technology have prompted doctors and researchers to transition their emphasis away from conventional diagnostic approaches toward personalized medicine. This shift reflects a growing recognition of the benefits of tailoring medical treatments and interventions to individual patient needs and characteristics, which support the market growth.

However, lack of skilled laboratory technicians is anticipated to hinder the market growth during the forecast period. However, rise in the number of diagnostic testing and technological advancements in DNA sequencing are expected to create lucrative opportunities for the market growth during the forecast period.

The in vitro diagnostics market is segmented into product & services, technique, application, end user, and region. By product & services, the market is categorized into reagents & kits, instruments, and software & services.

By technique, the market is divided into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. By application, the market is classified into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. By end user, the market is classified into standalone laboratories, hospitals, academic and medical schools, point of care, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global in vitro diagnostics market are Freenome Holdings, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., Exact Sciences Corporation, Guardant Health, Illumina, Inc., InterVenn Biosciences, NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific, Inc. Key players operating in the market have adopted product launch, acquisition, partnership, product approval, and expansion as key strategies to expand their market share and product portfolio.
Key Benefits for Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the in vitro diagnostics market analysis from 2022 to 2032 to identify the prevailing in vitro diagnostics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the in vitro diagnostics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global in vitro diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By End User

Standalone Laboratories
Hospitals
Academic and Medical Schools
Point of Care
Others

By Product and Services

Reagents and Kits
Instruments
Software and Services

By Technique

Molecular Diagnostics
Tissue Diagnostics
Clinical Chemistry
Others
Immunodiagnostics
Hematology

By Application

Infectious Diseases
Cancer
Cardiac Diseases
Immune System Disorders
Nephrological Diseases
Gastrointestinal Diseases
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

InterVenn Biosciences
Agilent Technologies, Inc.
Illumina, Inc.
Thermo Fisher Scientific, Inc.
NeoGenomics Laboratories
Exact Sciences Corporation
Freenome Holdings, Inc.
Natera, Inc.
F. Hoffmann-La Roche Ltd.
Guardant Health
Invitae Corporation

Product Code: A00245

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. High bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of chronic and infectious diseases
  - 3.4.1.2. Surge in awareness about early disease diagnosis and personalized medicine
  - 3.4.1.3. Rise in number of diagnostic laboratories
- 3.4.2. Restraints
  - 3.4.2.1. Stringent regulatory policies
- 3.4.3. Opportunities
  - 3.4.3.1. Technological advancements in IVD

CHAPTER 4: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT AND SERVICES

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Reagents and Kits
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Instruments
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Software and Services
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Immunodiagnostics
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Hematology
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Molecular Diagnostics
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Tissue Diagnostics
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. Clinical Chemistry
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
5.7. Others
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country

CHAPTER 6: IN VITRO DIAGNOSTICS MARKET, BY APPLICATION

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Infectious Diseases
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Cancer
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Cardiac Diseases
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
6.5. Immune System Disorders
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country
6.6. Nephrological Diseases
- 6.6.1. Key market trends, growth factors and opportunities
- 6.6.2. Market size and forecast, by region
- 6.6.3. Market share analysis by country
6.7. Gastrointestinal Diseases
- 6.7.1. Key market trends, growth factors and opportunities
- 6.7.2. Market size and forecast, by region
- 6.7.3. Market share analysis by country
6.8. Others
- 6.8.1. Key market trends, growth factors and opportunities
- 6.8.2. Market size and forecast, by region
- 6.8.3. Market share analysis by country

CHAPTER 7: IN VITRO DIAGNOSTICS MARKET, BY END USER

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Standalone Laboratories
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Hospitals
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
7.4. Academic and Medical Schools
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country
7.5. Point of Care
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by region
- 7.5.3. Market share analysis by country
7.6. Others
- 7.6.1. Key market trends, growth factors and opportunities
- 7.6.2. Market size and forecast, by region
- 7.6.3. Market share analysis by country

CHAPTER 8: IN VITRO DIAGNOSTICS MARKET, BY REGION

8.1. Overview
- 8.1.1. Market size and forecast By Region
8.2. North America
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by Product and Services
- 8.2.3. Market size and forecast, by Technique
- 8.2.4. Market size and forecast, by Application
- 8.2.5. Market size and forecast, by End User
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
  - 8.2.6.1.1. Market size and forecast, by Product and Services
  - 8.2.6.1.2. Market size and forecast, by Technique
  - 8.2.6.1.3. Market size and forecast, by Application
  - 8.2.6.1.4. Market size and forecast, by End User
  - 8.2.6.2. Canada
  - 8.2.6.2.1. Market size and forecast, by Product and Services
  - 8.2.6.2.2. Market size and forecast, by Technique
  - 8.2.6.2.3. Market size and forecast, by Application
  - 8.2.6.2.4. Market size and forecast, by End User
  - 8.2.6.3. Mexico
  - 8.2.6.3.1. Market size and forecast, by Product and Services
  - 8.2.6.3.2. Market size and forecast, by Technique
  - 8.2.6.3.3. Market size and forecast, by Application
  - 8.2.6.3.4. Market size and forecast, by End User
8.3. Europe
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by Product and Services
- 8.3.3. Market size and forecast, by Technique
- 8.3.4. Market size and forecast, by Application
- 8.3.5. Market size and forecast, by End User
- 8.3.6. Market size and forecast, by country
  - 8.3.6.1. Germany
  - 8.3.6.1.1. Market size and forecast, by Product and Services
  - 8.3.6.1.2. Market size and forecast, by Technique
  - 8.3.6.1.3. Market size and forecast, by Application
  - 8.3.6.1.4. Market size and forecast, by End User
  - 8.3.6.2. France
  - 8.3.6.2.1. Market size and forecast, by Product and Services
  - 8.3.6.2.2. Market size and forecast, by Technique
  - 8.3.6.2.3. Market size and forecast, by Application
  - 8.3.6.2.4. Market size and forecast, by End User
  - 8.3.6.3. UK
  - 8.3.6.3.1. Market size and forecast, by Product and Services
  - 8.3.6.3.2. Market size and forecast, by Technique
  - 8.3.6.3.3. Market size and forecast, by Application
  - 8.3.6.3.4. Market size and forecast, by End User
  - 8.3.6.4. Italy
  - 8.3.6.4.1. Market size and forecast, by Product and Services
  - 8.3.6.4.2. Market size and forecast, by Technique
  - 8.3.6.4.3. Market size and forecast, by Application
  - 8.3.6.4.4. Market size and forecast, by End User
  - 8.3.6.5. Spain
  - 8.3.6.5.1. Market size and forecast, by Product and Services
  - 8.3.6.5.2. Market size and forecast, by Technique
  - 8.3.6.5.3. Market size and forecast, by Application
  - 8.3.6.5.4. Market size and forecast, by End User
  - 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Market size and forecast, by Product and Services
  - 8.3.6.6.2. Market size and forecast, by Technique
  - 8.3.6.6.3. Market size and forecast, by Application
  - 8.3.6.6.4. Market size and forecast, by End User
8.4. Asia-Pacific
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by Product and Services
- 8.4.3. Market size and forecast, by Technique
- 8.4.4. Market size and forecast, by Application
- 8.4.5. Market size and forecast, by End User
- 8.4.6. Market size and forecast, by country
  - 8.4.6.1. Japan
  - 8.4.6.1.1. Market size and forecast, by Product and Services
  - 8.4.6.1.2. Market size and forecast, by Technique
  - 8.4.6.1.3. Market size and forecast, by Application
  - 8.4.6.1.4. Market size and forecast, by End User
  - 8.4.6.2. China
  - 8.4.6.2.1. Market size and forecast, by Product and Services
  - 8.4.6.2.2. Market size and forecast, by Technique
  - 8.4.6.2.3. Market size and forecast, by Application
  - 8.4.6.2.4. Market size and forecast, by End User
  - 8.4.6.3. India
  - 8.4.6.3.1. Market size and forecast, by Product and Services
  - 8.4.6.3.2. Market size and forecast, by Technique
  - 8.4.6.3.3. Market size and forecast, by Application
  - 8.4.6.3.4. Market size and forecast, by End User
  - 8.4.6.4. Australia
  - 8.4.6.4.1. Market size and forecast, by Product and Services
  - 8.4.6.4.2. Market size and forecast, by Technique
  - 8.4.6.4.3. Market size and forecast, by Application
  - 8.4.6.4.4. Market size and forecast, by End User
  - 8.4.6.5. South Korea
  - 8.4.6.5.1. Market size and forecast, by Product and Services
  - 8.4.6.5.2. Market size and forecast, by Technique
  - 8.4.6.5.3. Market size and forecast, by Application
  - 8.4.6.5.4. Market size and forecast, by End User
  - 8.4.6.6. Rest of Asia-Pacific
  - 8.4.6.6.1. Market size and forecast, by Product and Services
  - 8.4.6.6.2. Market size and forecast, by Technique
  - 8.4.6.6.3. Market size and forecast, by Application
  - 8.4.6.6.4. Market size and forecast, by End User
8.5. LAMEA
- 8.5.1. Key market trends, growth factors and opportunities
- 8.5.2. Market size and forecast, by Product and Services
- 8.5.3. Market size and forecast, by Technique
- 8.5.4. Market size and forecast, by Application
- 8.5.5. Market size and forecast, by End User
- 8.5.6. Market size and forecast, by country
  - 8.5.6.1. Brazil
  - 8.5.6.1.1. Market size and forecast, by Product and Services
  - 8.5.6.1.2. Market size and forecast, by Technique
  - 8.5.6.1.3. Market size and forecast, by Application
  - 8.5.6.1.4. Market size and forecast, by End User
  - 8.5.6.2. Saudi Arabia
  - 8.5.6.2.1. Market size and forecast, by Product and Services
  - 8.5.6.2.2. Market size and forecast, by Technique
  - 8.5.6.2.3. Market size and forecast, by Application
  - 8.5.6.2.4. Market size and forecast, by End User
  - 8.5.6.3. South Africa
  - 8.5.6.3.1. Market size and forecast, by Product and Services
  - 8.5.6.3.2. Market size and forecast, by Technique
  - 8.5.6.3.3. Market size and forecast, by Application
  - 8.5.6.3.4. Market size and forecast, by End User
  - 8.5.6.4. Rest of LAMEA
  - 8.5.6.4.1. Market size and forecast, by Product and Services
  - 8.5.6.4.2. Market size and forecast, by Technique
  - 8.5.6.4.3. Market size and forecast, by Application
  - 8.5.6.4.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

10.1. Freenome Holdings, Inc.
- 10.1.1. Company overview
- 10.1.2. Key executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Key strategic moves and developments
10.2. Natera, Inc.
- 10.2.1. Company overview
- 10.2.2. Key executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.2.6. Business performance
- 10.2.7. Key strategic moves and developments
10.3. Agilent Technologies, Inc.
- 10.3.1. Company overview
- 10.3.2. Key executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Business performance
- 10.3.7. Key strategic moves and developments
10.4. Exact Sciences Corporation
- 10.4.1. Company overview
- 10.4.2. Key executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.6. Business performance
- 10.4.7. Key strategic moves and developments
10.5. Illumina, Inc.
- 10.5.1. Company overview
- 10.5.2. Key executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.5.6. Business performance
- 10.5.7. Key strategic moves and developments
10.6. F. Hoffmann-La Roche Ltd.
- 10.6.1. Company overview
- 10.6.2. Key executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Business performance
- 10.6.7. Key strategic moves and developments
10.7. Guardant Health
- 10.7.1. Company overview
- 10.7.2. Key executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
- 10.7.6. Business performance
- 10.7.7. Key strategic moves and developments
10.8. InterVenn Biosciences
- 10.8.1. Company overview
- 10.8.2. Key executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
- 10.8.6. Key strategic moves and developments
10.9. Thermo Fisher Scientific, Inc.
- 10.9.1. Company overview
- 10.9.2. Key executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Business performance
- 10.9.7. Key strategic moves and developments
10.10. Invitae Corporation
- 10.10.1. Company overview
- 10.10.2. Key executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- 10.10.6. Business performance
- 10.10.7. Key strategic moves and developments
10.11. NeoGenomics Laboratories
- 10.11.1. Company overview
- 10.11.2. Key executives
- 10.11.3. Company snapshot
- 10.11.4. Operating business segments
- 10.11.5. Product portfolio
- 10.11.6. Business performance
- 10.11.7. Key strategic moves and developments